Psychoactive Substances: Analytical Strategies for the Identification of Designer Drugs in Forensic and Clinical Contexts

Document Type : Review Article(s)

Authors

Department of Pharmaceutical Analysis, School of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, Andhra Pradesh, India

10.34172/ahj.1707

Abstract

Introduction: Designer drugs, or novel psychoactive substances (NPS), are synthetic analogues of controlled drugs engineered to mimic their pharmacological effects while evading legal regulation. Their rapid emergence and global distribution pose major challenges to public health, law enforcement, and analytical laboratories due to their unpredictable effects and complex chemical variability.
Methods: This review compiled and analyzed recent literature on the classification, pharmacology, abuse patterns, and analytical detection of designer drugs. Key instrumental techniques such as gas chromatography–mass spectrometry (GC-MS), liquid chromatography–tandem mass spectrometry (LC-MS/MS), and nuclear magnetic resonance (NMR) were evaluated alongside novel sensor-based technologies. Relevant case studies were examined to highlight clinical and forensic implications.
Findings: The major classes of designer drugs include synthetic cathinones, cannabinoids, benzodiazepines, phenidate derivatives, and dissociatives. Traditional analytical methods provide high sensitivity and selectivity but face challenges like matrix effects, derivatization needs, and limited on-site applicability. Emerging sensor technologies, including molecularly imprinted polymers and aptamer-based biosensors, offer rapid and portable alternatives for field testing. GC-MS and LC-MS/MS remain the gold standards for confirmatory testing, while innovative nano-enabled sensors show promise for real-time detection and point-of-care diagnostics.
Conclusion: Continuous evolution of designer drugs necessitates adaptable analytical strategies. Integration of advanced sensor platforms with established chromatographic methods and strengthened inter-laboratory validation can enhance global surveillance and improve public health responses to NPS abuse.

Highlights

Nalanda Revu(GoogleScholar)

Keywords

References

  1. Luethi D, Liechti ME. Designer drugs: mechanism of action and adverse effects. Arch Toxicol 2020;94(4):1085-133. doi:10.1007/s00204-020-02693-7
  2. Noggle FT, Clark CR, Bouhadir KH, DeRuiter J. Methods for the differentiation of methamphetamine from regioisomeric phenethylamines. J Chromatogr Sci 1991;29(1):31-6. doi:10.1093/chromsci/29.1.31
  3. Maresová V, Chadt J, Prikryl L. Simultaneous determination of amphetamines and amphetamine-derived designer drugs in human urine by GC-MS. Neuro Endocrinol Lett 2006;27 Suppl 2:121-4.
  4. Sasaki T, Makino Y. Effective injection in pulsed splitless mode for impurity profiling of methamphetamine crystal by GC or GC/MS. Forensic Sci Int 2006;160(1):1-10. doi:10.1016/j. forsciint.2005.07.019
  5. Mitrevski B, Zdravkovski Z. Rapid and simple method for direct determination of several amphetamines in seized tablets by GC- -FID. Forensic Sci Int 2005;152(2-3):199-203. doi:10.1016/j. forsciint.2004.08.010
  6. Sachs SB, Woo F. A detailed mechanistic fragmentation analysis of methamphetamine and select regioisomers by GC/ MS. J Forensic Sci 2007;52(2):308-19. doi:10.1111/j.1556- 4029.2007.00401.x
  7. Liu Z, Hara K, Kashimura S, Liu J, Fujii H, Kashiwagi M, et al. Two simple methods for enantiomeric analyses of urinary amphetamines by GC/MS using deuterium-labeled l-amphetamines as internal standards. Forensic Toxicol 2006;24(1):2-7. doi:10.1007/s11419-006-0001-7
  8. Awad T, Deruiter J, Clark CR. Chromatographic and mass spectral studies on methoxy methyl methamphetamines related to 3,4-methylenedioxymethamphetamine. J Chromatogr Sci 2007;45(8):466-76. doi:10.1093/chromsci/45.8.466
  9. Rose AR, Joshi M, Staretz ME, Wood M, Brettell TA. GC-MS analysis of eight aminoindanes using three derivatization reagents. J Forensic Sci 2023;68(4):1148-61. doi:10.1111/1556- 4029.15299
  10. Fowble KL, Shepard JRE, Musah RA. Identification and classification of cathinone unknowns by statistical analysis processing of direct analysis in real time-high resolution mass spectrometry-derived “neutral loss” spectra. Talanta 2018;179:546-53. doi:10.1016/j.talanta.2017.11.020
  11. Zhang JX, Zhang DM, Han XG. Identification of impurities and statistical classification of methamphetamine hydrochloride drugs seized in China. Forensic Sci Int 2008;182(1-3):13-9. doi:10.1016/j.forsciint.2008.09.012
  12. Fabregat-Safont D, Carbón X, Gil C, Ventura M, Sancho JV, Hernández F, et al. Reporting the novel synthetic cathinone 5-PPDI through its analytical characterization by mass spectrometry and nuclear magnetic resonance. Forensic Toxicol 2018;36(2):447-57. doi:10.1007/s11419-018-0422-0
  13. Sisco E, Burns A, Moorthy AS. Development and evaluation of a synthetic cathinone targeted gas chromatography mass spectrometry (GC-MS) method. J Forensic Sci 2021;66(5):1919- 28. doi:10.1111/1556-4029.14789
  14. Westphal F, Junge T, Rösner P, Sönnichsen F, Schuster F. Mass and NMR spectroscopic characterization of 3,4-methylenedioxypyrovalerone: a designer drug with alpha-pyrrolidinophenone structure. Forensic Sci Int 2009;190(1-3):1- 8. doi:10.1016/j.forsciint.2009.05.001
  15. Salerno TM, Donato P, Frison G, Zamengo L, Mondello L. Gas chromatography-Fourier transform infrared spectroscopy for unambiguous determination of illicit drugs: a proof of concept. Front Chem 2020;8:624. doi:10.3389/fchem.2020.00624
  16. Namera A, Kawamura M, Nakamoto A, Saito T, Nagao M. Comprehensive review of the detection methods for synthetic cannabinoids and cathinones. Forensic Toxicol 2015;33(2):175- 94. doi:10.1007/s11419-015-0270-0
  17. Cheng SY, Ng-A-Qui T, Eng B, Ho J. Detection of cathinone and mephedrone in plasma by LC-MS/MS using standard addition quantification technique. J Anal Sci Technol 2017;8(1):19. doi:10.1186/s40543-017-0128-7
  18. Lho DS, Lee J, Kim S, Park J, Shin HS. Identification of a pyrovalerone metabolite in the rat by gas chromatography-mass spectrometry and determination of pyrovalerone by gas chromatography-nitrogen-phosphorus detection. J Chromatogr B Biomed Appl 1996;687(1):253-9. doi:10.1016/s0378- 4347(96)00183-1
  19. Shin HS, Shin YS, Lee S, Park BB. Detection and identification of pyrovalerone and its hydroxylated metabolite in the rat. J Anal Toxicol 1996;20(7):568-72. doi:10.1093/jat/20.7.568
  20. de Boer D, Bosman IJ, Hidvégi E, Manzoni C, Benkö AA, dos Reys LJ, et al. Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market. Forensic Sci Int 2001;121(1-2):47-56. doi:10.1016/s0379-0738(01)00452-2
  21. Shi H, Sun J, Han R, Ding C, Hu F, Yu S. The strategy for correcting interference from water in Fourier transform infrared spectrum based bacterial typing. Talanta 2020;208:120347. doi:10.1016/j.talanta.2019.120347
  22. Persona K, Verget J, Przybyłowicz A, Gomółka E, Piekoszewski W. Determination of N-benzylpiperazine in human plasma using derivatization-free liquid–liquid extraction and gas chromatography mass spectrometry. Anal Methods 2013;5(18):4805-10. doi:10.1039/c3ay40892b
  23. Shamai Yamin T, Prihed H, Madmon M, Shifrovitch A, Baratz A, Weissberg A. Structural elucidation of phenidate analogues via the ESI-MS/MS spectra of their sodium adduct ions. Forensic Sci Int 2020;306:110044. doi:10.1016/j.forsciint.2019.110044
  24. Paterson SM, Moore GA, Florkowski CM, George PM. Determination of methylphenidate and its metabolite ritalinic acid in urine by liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2012;881-882:20-6. doi:10.1016/j.jchromb.2011.11.007
  25. Chari G, Gulati A, Bhat R, Tebbett IR. High-performance liquid chromatographic determination of morphine, morphine-3- glucuronide, morphine-6-glucuronide and codeine in biological samples using multi-wavelength forward optical detection. J Chromatogr 1991;571(1-2):263-70. doi:10.1016/0378- 4347(91)80454-k
  26. Pawula M, Barrett DA, Shaw PN. An improved extraction method for the HPLC determination of morphine and its metabolites in plasma. J Pharm Biomed Anal 1993;11(4-5):401- 6. doi:10.1016/0731-7085(93)80036-z
  27. Wei Q, Su FH. Determination of nine fentanyl drugs in hair samples by GC-MS/MS and LC-MS/MS. ACS Omega 2022;7(23):19176-82. doi:10.1021/acsomega.2c00087
  28. Hudson S, Ramsey J. The emergence and analysis of synthetic cannabinoids. Drug Test Anal 2011;3(7-8):466-78. doi:10.1002/ dta.268
  29. Wiley JL, Marusich JA, Huffman JW, Balster RL, Thomas BF. Hijacking of basic research: the case of synthetic cannabinoids. Methods Rep RTI Press 2011;2011. doi:10.3768/rtipress.2011. op.0007.1111
  30. Wu J, Zhang F, Ke X, Jia W, Wan X, Zhang L, et al. Rapid simultaneous determination of 11 synthetic cannabinoids in urine by liquid chromatography-triple quadrupole mass spectrometry. Separations 2023;10(3):203. doi:10.3390/ separations10030203
  31. Staack RF, Maurer HH. New designer drug 1-(3,4-methylenedioxybenzyl) piperazine (MDBP): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J Mass Spectrom 2004;39(3):255-61. doi:10.1002/jms.556
  32. Lua AC, Lin HR. A rapid and sensitive ESI-MS screening procedure for ketamine and norketamine in urine samples. J Anal Toxicol 2004;28(8):680-4. doi:10.1093/jat/28.8.680
  33. Moore KA, Sklerov J, Levine B, Jacobs AJ. Urine concentrations of ketamine and norketamine following illegal consumption. J Anal Toxicol 2001;25(7):583-8. doi:10.1093/jat/25.7.583
  34. Huang MK, Liu C, Li JH, Huang SD. Quantitative detection of ketamine, norketamine, and dehydronorketamine in urine using chemical derivatization followed by gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005;820(2):165-73. doi:10.1016/j.jchromb.2005.03.004
  35. Di Francesco G, Montesano C, Vincenti F, Bilel S, Corli G, Petrella G, et al. Tackling new psychoactive substances through metabolomics: UHPLC-HRMS study on natural and synthetic opioids in male and female murine models. Sci Rep 2024;14(1):9432. doi:10.1038/s41598-024-60045-2
  36. Richeval C, Gicquel T, Hugbart C, Le Dare B, Allorge D, Morel I, et al. In vitro characterization of NPS metabolites produced by human liver microsomes and the HepaRG cell line using liquid chromatographyhigh resolution mass spectrometry (LC-HRMS) analysis: application to furanyl fentanyl. Curr Pharm Biotechnol 2017;18(10):806-14. doi:10.2174/13892010186 66171122124401
  37. Concheiro M, Castaneto M, Kronstrand R, Huestis MA. Simultaneous determination of 40 novel psychoactive stimulants in urine by liquid chromatography-high resolution mass spectrometry and library matching. J Chromatogr A 2015;1397:32-42. doi:10.1016/j.chroma.2015.04.002
  38. Fiehn O. Metabolomics by gas chromatography-mass spectrometry: combined targeted and untargeted profiling. Curr Protoc Mol Biol 2016;114:30.4.1-32. doi:10.1002/0471142727. mb3004s114
  39. Strathmann FG, Lynch KL, Krotulski A, Negri P, Cichelli J, Meyer MR. Challenges of high-resolution mass spectrometry for detecting designer drugs. Clin Chem 2020;66(7):868-74. doi:10.1093/clinchem/hvaa118
  40. Emwas AH, Roy R, McKay RT, Tenori L, Saccenti E, Gowda GA, et al. NMR spectroscopy for metabolomics research. Metabolites 2019;9(7):123. doi:10.3390/metabo9070123
  41. Lin Y, Caldwell GW, Li Y, Lang W, Masucci J. Inter-laboratory reproducibility of an untargeted metabolomics GC-MS assay for analysis of human plasma. Sci Rep 2020;10(1):10918. doi:10.1038/s41598-020-67939-x
  42. Zhang N, Chen Q, Zhang P, Zhou K, Liu Y, Wang H, et al. Quartet metabolite reference materials for inter-laboratory proficiency test and data integration of metabolomics profiling. Genome Biol 2024;25(1):34. doi:10.1186/s13059-024-03168-z
  43. Pelletier R, Nahle D, Sarr M, Bourdais A, Morel I, Le Daré B, et al. Identifying metabolites of new psychoactive substances using in silico prediction tools. Arch Toxicol 2025;99(7):2953- 73. doi:10.1007/s00204-025-04049-5
  44. Takase I, Koizumi T, Fujimoto I, Yanai A, Fujimiya T. An autopsy case of acetyl fentanyl intoxication caused by insufflation of ‘designer drugs’. Leg Med (Tokyo) 2016;21:38- 44. doi:10.1016/j.legalmed.2016.05.006
  45. Alzu’bi A, Almahasneh F, Khasawneh R, Abu-El-Rub E, Baker WB, Al-Zoubi RM. The synthetic cannabinoids menace: a review of health risks and toxicity. Eur J Med Res 2024;29(1):49. doi:10.1186/s40001-023-01443-6
  46. Hamburg BA, Kraemer HC, Jahnke W. A hierarchy of drug use in adolescene: behavioral and attitudinal correlates of substantial drug use. Am J Psychiatry 1975;132(11):1155-63. doi:10.1176/ajp.132.11.1155
  47. Childs E, Lutz JA, de Wit H. Dose-related effects of Delta-9- THC on emotional responses to acute psychosocial stress. Drug Alcohol Depend 2017;177:136-44. doi:10.1016/j. drugalcdep.2017.03.030
  48. Saylan Y, Akgönüllü S, Yavuz H, Ünal S, Denizli A. Molecularly imprinted polymer-based sensors for medical applications. Sensors (Basel) 2019;19(6):1279. doi:10.3390/s19061279
  49. Kawano R, Osaki T, Sasaki H, Takinoue M, Yoshizawa S, Takeuchi S. Rapid detection of a cocaine-binding aptamer using biological nanopores on a chip. J Am Chem Soc 2011;133(22):8474-7. doi:10.1021/ja2026085
  50. Wang J, Hou J, Zhang H, Tian Y, Jiang L. Single nanochannel-aptamer-based biosensor for ultrasensitive and selective cocaine detection. ACS Appl Mater Interfaces 2018;10(2):2033- 9. doi:10.1021/acsami.7b16539
  51. Zhang Q, Berg D, Mugo SM. Molecularly imprinted carbon-based electrodes for tetrahydrocannabinol sensing. Inorg Chem Commun 2019;107:107459. doi:10.1016/j. inoche.2019.107459
  52. Majdinasab M, Mitsubayashi K, Marty JL. Optical and electrochemical sensors and biosensors for the detection of quinolones. Trends Biotechnol 2019;37(8):898-915. doi:10.1016/j.tibtech.2019.01.004
  53. Kolbrich EA, Barnes AJ, Gorelick DA, Boyd SJ, Cone EJ, Huestis MA. Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration. J Anal Toxicol 2006;30(8):501-10. doi:10.1093/jat/30.8.501
  54. Wang W, He Y, He S, Deng L, Wang H, Cao Z, et al. A brief review of aptamer-based biosensors in recent years. Biosensors (Basel) 2025;15(2):120. doi:10.3390/bios15020120
  55. Jarczewska M, Górski Ł, Malinowska E. Electrochemical aptamer-based biosensors as potential tools for clinical diagnostics. Anal Methods 2016;8(19):3861-77. doi:10.1039/ c6ay00499g
  56. Aller Pellitero M, de-los-Santos-Álvarez N, Lobo-Castañón MJ. Aptamer-based electrochemical approaches to meet some of the challenges in the fight against cancer. Curr Opin Electrochem 2023;39:101286. doi:10.1016/j.coelec.2023.101286
  57. White RJ, Phares N, Lubin AA, Xiao Y, Plaxco KW. Optimization of electrochemical aptamer-based sensors via optimization of probe packing density and surface chemistry. Langmuir 2008;24(18):10513-8. doi:10.1021/la800801v
  58. Vardanyan RS, Hruby VJ. Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications. Future Med Chem 2014;6(4):385- 412. doi:10.4155/fmc.13.215
  59. Barfidokht A, Mishra RK, Seenivasan R, Liu S, Hubble LJ, Wang J, et al. Wearable electrochemical glove-based sensor for rapid and on-site detection of fentanyl. Sens Actuators B Chem 2019;296. doi:10.1016/j.snb.2019.04.053
  60. Dagar M, Yadav S, Sai VV, Satija J, Bhatia H. Emerging trends in point-of-care sensors for illicit drugs analysis. Talanta 2022;238(Pt 2):123048. doi:10.1016/j.talanta.2021.123048
  61. Adegoke O, Zolotovskaya S, Abdolvand A, Daeid NN. Biomimetic graphene oxide-cationic multi-shaped gold nanoparticle-hemin hybrid nanozyme: tuning enhanced catalytic activity for the rapid colorimetric apta-biosensing of amphetamine-type stimulants. Talanta 2020;216:120990. doi:10.1016/j.talanta.2020.120990
  62. Lee JR, Choi J, Shultz TO, Wang SX. Small molecule detection in saliva facilitates portable tests of marijuana abuse. Anal Chem 2016;88(15):7457-61. doi:10.1021/acs.analchem.6b01688
  63. Brunetti P, Giorgetti R, Tagliabracci A, Huestis MA, Busardò FP. Designer benzodiazepines: a review of toxicology and public health risks. Pharmaceuticals (Basel) 2021;14(6):560. doi:10.3390/ph14060560
  64. Sharma TK, Ramanathan R, Weerathunge P, Mohammadtaheri M, Daima HK, Shukla R, et al. Aptamer-mediated ‘turn-off/ turn-on’ nanozyme activity of gold nanoparticles for kanamycin detection. Chem Commun (Camb) 2014;50(100):15856-9. doi:10.1039/c4cc07275h
  65. Weerathunge P, Ramanathan R, Shukla R, Sharma TK, Bansal V. Aptamer-controlled reversible inhibition of gold nanozyme activity for pesticide sensing. Anal Chem 2014;86(24):11937- 41. doi:10.1021/ac5028726
  66. Gonsalves H, dos Santos AF, Azevedo LH, Corrêa L. Immunohistochemical expression of survivin in oral biopsies taken with surgical laser compared to scalpel. Oral Sur Oral Med Oral Pathol Oral Radiol 2025;139(5): e131. doi:10.1016/j. oooo.2025.01.638
  67. Kaur H, Bruno JG, Kumar A, Sharma TK. Aptamers in the therapeutics and diagnostics pipelines. Theranostics 2018;8(15):4016-32. doi:10.7150/thno.25958
  68. Zhang X, Servos MR, Liu J. Surface science of DNA adsorption onto citrate-capped gold nanoparticles. Langmuir 2012;28(8):3896-902. doi:10.1021/la205036p
  69. Nguyen LH, Chong NM. Development of an ATP measurement method suitable for xenobiotic treatment activated sludge biomass. J Chromatogr B Analyt Technol Biomed Life Sci 2015;1000:69-76. doi:10.1016/j.jchromb.2015.07.005
  70. van Wijk XM, Yun C, Hooshfar S, Arens AM, Lung D, Wu AHB, et al. A liquid-chromatography high-resolution mass spectrometry method for non-FDA approved benzodiazepines. J Anal Toxicol 2019;43(4):316-20. doi:10.1093/jat/bky092
  71. El Balkhi S, Chaslot M, Picard N, Dulaurent S, Delage M, Mathieu O, et al. Characterization and identification of eight designer benzodiazepine metabolites by incubation with human liver microsomes and analysis by a triple quadrupole mass spectrometer. Int J Legal Med 2017;131(4):979-88. doi:10.1007/s00414-017-1541-6
  72. O’Neal CL, Crouch DJ, Fatah AA. Validation of twelve chemical spot tests for the detection of drugs of abuse. Forensic Sci Int 2000;109(3):189-201. doi:10.1016/s0379-0738(99)00235-2
  73. Harper L, Powell J, Pijl EM. An overview of forensic drug testing methods and their suitability for harm reduction point-of-care services. Harm Reduct J 2017;14(1):52. doi:10.1186/s12954- 017-0179-5
  74. Canoura J, Alkhamis O, Venzke M, Ly PT, Xiao Y. Developing aptamer-based colorimetric opioid tests. JACS Au 2024;4(3):1059-72. doi:10.1021/jacsau.3c00801
  75. Syrjanen R, Dutch M, Greene SL, Lyons T, McKinnon G, Gerostamoulos D, et al. Novel harm reduction measures at music festivals in Australia: pilot implementation of the Emerging Drugs Network of Australia-Victoria toxicosurveillance methodology. Drug Alcohol Rev 2024;43(7):2045-54. doi:10.1111/dar.13922
  76. Cohen A, Vakharia SP, Netherland J, Frederique K. How the war on drugs impacts social determinants of health beyond the criminal legal system. Ann Med 2022;54(1):2024-38. doi:10.1 080/07853890.2022.2100926
Addiction & Health
Volume 18
Pages 1-13

Files

Share

How to cite

Statistics